245: The rates of abnormal glucose challenge tests and gestational diabetes are not increased in women receiving 17-hydroxyprogesterone caproatefor the prevention of preterm delivery: a case-control study

Two previous retrospective studies reported an increased rate of gestational diabetes (GDM) in patients receiving IM 17-hydroxyprogesterone caproate (17P) for prevention of recurrent preterm delivery (PTD). Our objective is to determine whether the rates of abnormal glucose challenge test (GCT 135mg/dL) and GDM are increased in women receiving 17P early in pregnancy for prevention of PTD. A prospective cohort study of patients with a history of previous PTD in the antecedent pregnancy followed in a high-risk pregnancy clinic were offered IM 17P weekly until 36 completed weeks. Patients had routine GCT as per protocol; those with a value 135mg/dL received OGTT. GDM was defined according to Carpenter/Coustan criteria. Results of GCT and rate of GDM were compared between those receiving 17P and those not receiving therapy. Sixty-five women received 17P and 85 did not (Table). Maternal age in years (26.7, 26.9), age >30 (31%, 23.6%), BMI (26.9, 29.0), history of gestational diabetes (12.7%, 11.6%), parity (4.5, 4.0) and maternal race (45% and 64% African American) were similar between 17P and no 17P groups. The 17P group received an average of 6.9 doses prior to GCT. The odds ratios were calculated using a multiple logistic regression analysis. Mean glucose values, rate of abnormal GCT and rate of GDM were similar between groups (Table).Tabled 117P N=65No 17P N=85OR (95%CI)Mean Plasma GCT (mg/dL)106.9 ± 35.7* not significant110.3± 32.0 * not significantGCT ≥135 mg/dL12 (18.5%)15 (17.6%)1.1 (0.5-2.4)GDM2 (3.1%)7 (8.2%)0.4 (0.07-1.8) Open table in a new tab Contrary to previous reports, we found in this prospective study that 17P administration to patients at risk of recurrent preterm delivery did not affect glucose tolerance.